WuXi Biologics (OTCPK ... development and manufacturing organization, or CRDMO, has agreed to sell the plant to Merck (NYSE:MRK) for around $500M, according to Reuters. In late December, WuXi ...

Merck can now integrate vaccine production within its own manufacturing network to supply global markets while WuXi Biologics focuses on providing contract vaccine services from its sites in ...

At the heart of this evolution lies the growing prominence of biologics contract manufacturing, a strategic partnership that is reshaping the way pharmaceutical companies approach their production ...

Jan 6 (Reuters) - China's WuXi Biologics (2269.HK), opens new tab said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co (MRK.N), opens new tab for about $500 ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing Consortium aimed at pioneering new advances in how medicines are produced.

WuXi 2269-0.22%decrease; red down pointing triangle Biologics agreed to sell an overseas vaccine facility to Merck MRK-0.50 ... three-story vaccine manufacturing plant with 200 employees.

WuXi Biologics said in the filing. For Merck, the deal will help it better integrate vaccine production within its global manufacturing network, it said. Hong Kong-listed shares of the Chinese ...

Merck can now integrate vaccine production within its own manufacturing network to supply global markets while WuXi Biologics focuses on providing contract vaccine services from its sites in Suzhou, ...